A Study of WF 10 IV Solution in Patients With Advanced HIV Disease

Inclusion Criteria Concurrent Medication: Allowed: * Approved drugs at a stabilized dose except those specifically excluded. * Aerosolized pentamidine (300 mg) once a month for PCP prophylaxis. Patients must have: * HIV positivity. * Absolute CD4 count \< 200 cells/mm3. * Intolerance to or refusal to take AZT, ddI, ddC, or d4T. * No active opportunistic infection requiring ongoing therapy. * Life expectancy at least 3 months. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Neoplasm other than basal cell carcinoma of the skin. * Clinically significant cardiac disease. * Anemia. Concurrent Medication: Excluded: * Cytotoxic chemotherapy. * Corticosteroids. Patients with the following prior conditions are excluded: History of myocardial infarction or arrhythmias. Prior Medication: Excluded within 2 weeks prior to study entry: * Any antiretroviral agent. * Interferon. * Systemic therapy with biologic response modifiers, corticosteroids, cytotoxic chemotherapy, or neutropenic or nephrotoxic drugs. Excluded within 30 days prior to study entry: * Investigational drugs. Prior Treatment: Excluded within 2 weeks prior to study entry: * Radiation therapy. Active drug or alcohol abuse.